Back to top

crispr: Archive

Ahan Chakraborty

Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

VRTXPositive Net Change EDITPositive Net Change CRSPPositive Net Change ALXOPositive Net Change